Table of Content

Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 North America Antibody Drug Conjugates Market, by Application
1.4.2 North America Antibody Drug Conjugates Market, by Technology
1.4.3 North America Antibody Drug Conjugates Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Competition Analysis - Global
3.1 KBV Cardinal Matrix
3.2 Recent Industry Wide Strategic Developments
3.2.1 Partnerships, Collaborations and Agreements
3.2.2 Acquisition & mergers
3.2.3 Approvals and Trials
3.3 Top Winning Strategies
3.3.1 Key Leading Strategies: Percentage Distribution (2018-2022)
3.3.2 Key Strategic Move: (Partnerships, Collaborations & Agreements : 2018, May – 2022, Mar) Leading Players
Chapter 4. North America Antibody Drug Conjugates Market by Application
4.1 North America Breast Cancer Market by Country
4.2 North America Blood Cancer Market by Country
4.3 North America Urothelial Cancer & Bladder Cancer?Market by Country
4.4 North America Others Market by Country
Chapter 5. North America Antibody Drug Conjugates Market by Technology
5.1 North America Cleavable Linker Market by Country
5.2 North America Non-Cleavable Linker Market by Country
5.3 North America Others Market by Country
Chapter 6. North America Antibody Drug Conjugates Market by Country
6.1 US Antibody Drug Conjugates Market
6.1.1 US Antibody Drug Conjugates Market by Application
6.1.2 US Antibody Drug Conjugates Market by Technology
6.2 Canada Antibody Drug Conjugates Market
6.2.1 Canada Antibody Drug Conjugates Market by Application
6.2.2 Canada Antibody Drug Conjugates Market by Technology
6.3 Mexico Antibody Drug Conjugates Market
6.3.1 Mexico Antibody Drug Conjugates Market by Application
6.3.2 Mexico Antibody Drug Conjugates Market by Technology
6.4 Rest of North America Antibody Drug Conjugates Market
6.4.1 Rest of North America Antibody Drug Conjugates Market by Application
6.4.2 Rest of North America Antibody Drug Conjugates Market by Technology
Chapter 7. Company Profiles
7.1 Takeda Pharmaceutical Company Limited
7.1.1 Company Overview
7.1.2 Financial Analysis
7.1.3 Regional Analysis
7.1.4 Research & Development Expense
7.1.1 Recent strategies and developments:
7.1.1.1 Partnerships, Collaborations, and Agreements:
7.1.1.2 Acquisitions and Mergers:
7.2 F. Hoffmann-La Roche Ltd.
7.2.1 Company Overview
7.2.2 Financial Analysis
7.2.3 Segmental and Regional Analysis
7.2.4 Research & Development Expense
7.2.5 Recent strategies and developments:
7.2.5.1 Partnerships, Collaborations, and Agreements:
7.3 AstraZeneca PLC
7.3.1 Company Overview
7.3.2 Financial Analysis
7.3.3 Regional Analysis
7.3.4 Research & Development Expenses
7.3.5 Recent strategies and developments:
7.3.5.1 Partnerships, Collaborations, and Agreements:
7.4 GlaxoSmithKline PLC
7.4.1 Company Overview
7.4.2 Financial Analysis
7.4.3 Segmental and Regional Analysis
7.4.4 Research & Development Expense
7.4.5 Recent strategies and developments:
7.4.5.1 Partnerships, Collaborations, and Agreements:
7.4.5.2 Approvals and Trials:
7.5 Pfizer, Inc.
7.5.1 Company Overview
7.5.2 Financial Analysis
7.5.3 Regional & Segmental Analysis
7.5.4 Research & Development Expense
7.5.5 Recent strategies and developments:
7.5.5.1 Partnerships, Collaborations and Agreements:
7.6 Astellas Pharma, Inc.
7.6.1 Company Overview
7.6.2 Financial Analysis
7.6.3 Regional Analysis
7.6.4 Research & Development Expense
7.6.5 Recent strategies and developments:
7.6.5.1 Partnerships, Collaborations, and Agreements:
7.6.5.2 Approvals and Trials:
7.7 Gilead Sciences, Inc.
7.7.1 Company overview
7.7.2 Financial Analysis
7.7.3 Research & Development Expenses
7.7.4 Recent strategies and developments:
7.7.4.1 Acquisitions and Mergers:
7.7.4.2 Partnerships, Collaborations and Agreements:
7.8 Seagen, Inc.
7.8.1 Company Overview
7.8.2 Financial Analysis
7.8.3 Research & Development Expenses
7.8.4 Recent strategies and developments:
7.8.4.1 Partnerships, Collaborations, and Agreements:
7.9 ADC Therapeutics SA
7.9.1 Company Overview
7.9.2 Financial Analysis
7.9.3 Research & Development Expenses
7.9.4 Recent strategies and developments:
7.9.4.1 Partnerships, Collaborations, and Agreements:
7.9.4.2 Approvals and Trials:
7.10. Daiichi Sankyo Company, Limited
7.10.1 Company Overview
7.10.2 Financial Analysis
7.10.3 Research & Development Expense
7.10.4 Recent strategies and developments:
7.10.4.1 Partnerships, Collaborations, and Agreements:



List of Tables

TABLE 1 North America Antibody Drug Conjugates Market, 2018 - 2021, USD Million
TABLE 2 North America Antibody Drug Conjugates Market, 2022 - 2028, USD Million
TABLE 3 Partnerships, Collaborations and Agreements– Antibody Drug Conjugates Market
TABLE 4 Acquisition & mergers – Antibody Drug Conjugates Market
TABLE 5 Approvals and trials– Antibody Drug Conjugates Market
TABLE 6 North America Antibody Drug Conjugates Market by Application, 2018 - 2021, USD Million
TABLE 7 North America Antibody Drug Conjugates Market by Application, 2022 - 2028, USD Million
TABLE 8 North America Breast Cancer Market by Country, 2018 - 2021, USD Million
TABLE 9 North America Breast Cancer Market by Country, 2022 - 2028, USD Million
TABLE 10 North America Blood Cancer Market by Country, 2018 - 2021, USD Million
TABLE 11 North America Blood Cancer Market by Country, 2022 - 2028, USD Million
TABLE 12 North America Urothelial Cancer & Bladder Cancer?Market by Country, 2018 - 2021, USD Million
TABLE 13 North America Urothelial Cancer & Bladder Cancer?Market by Country, 2022 - 2028, USD Million
TABLE 14 North America Others Market by Country, 2018 - 2021, USD Million
TABLE 15 North America Others Market by Country, 2022 - 2028, USD Million
TABLE 16 North America Antibody Drug Conjugates Market by Technology, 2018 - 2021, USD Million
TABLE 17 North America Antibody Drug Conjugates Market by Technology, 2022 - 2028, USD Million
TABLE 18 North America Cleavable Linker Market by Country, 2018 - 2021, USD Million
TABLE 19 North America Cleavable Linker Market by Country, 2022 - 2028, USD Million
TABLE 20 North America Non-Cleavable Linker Market by Country, 2018 - 2021, USD Million
TABLE 21 North America Non-Cleavable Linker Market by Country, 2022 - 2028, USD Million
TABLE 22 North America Others Market by Country, 2018 - 2021, USD Million
TABLE 23 North America Others Market by Country, 2022 - 2028, USD Million
TABLE 24 North America Antibody Drug Conjugates Market by Country, 2018 - 2021, USD Million
TABLE 25 North America Antibody Drug Conjugates Market by Country, 2022 - 2028, USD Million
TABLE 26 US Antibody Drug Conjugates Market, 2018 - 2021, USD Million
TABLE 27 US Antibody Drug Conjugates Market, 2022 - 2028, USD Million
TABLE 28 US Antibody Drug Conjugates Market by Application, 2018 - 2021, USD Million
TABLE 29 US Antibody Drug Conjugates Market by Application, 2022 - 2028, USD Million
TABLE 30 US Antibody Drug Conjugates Market by Technology, 2018 - 2021, USD Million
TABLE 31 US Antibody Drug Conjugates Market by Technology, 2022 - 2028, USD Million
TABLE 32 Canada Antibody Drug Conjugates Market, 2018 - 2021, USD Million
TABLE 33 Canada Antibody Drug Conjugates Market, 2022 - 2028, USD Million
TABLE 34 Canada Antibody Drug Conjugates Market by Application, 2018 - 2021, USD Million
TABLE 35 Canada Antibody Drug Conjugates Market by Application, 2022 - 2028, USD Million
TABLE 36 Canada Antibody Drug Conjugates Market by Technology, 2018 - 2021, USD Million
TABLE 37 Canada Antibody Drug Conjugates Market by Technology, 2022 - 2028, USD Million
TABLE 38 Mexico Antibody Drug Conjugates Market, 2018 - 2021, USD Million
TABLE 39 Mexico Antibody Drug Conjugates Market, 2022 - 2028, USD Million
TABLE 40 Mexico Antibody Drug Conjugates Market by Application, 2018 - 2021, USD Million
TABLE 41 Mexico Antibody Drug Conjugates Market by Application, 2022 - 2028, USD Million
TABLE 42 Mexico Antibody Drug Conjugates Market by Technology, 2018 - 2021, USD Million
TABLE 43 Mexico Antibody Drug Conjugates Market by Technology, 2022 - 2028, USD Million
TABLE 44 Rest of North America Antibody Drug Conjugates Market, 2018 - 2021, USD Million
TABLE 45 Rest of North America Antibody Drug Conjugates Market, 2022 - 2028, USD Million
TABLE 46 Rest of North America Antibody Drug Conjugates Market by Application, 2018 - 2021, USD Million
TABLE 47 Rest of North America Antibody Drug Conjugates Market by Application, 2022 - 2028, USD Million
TABLE 48 Rest of North America Antibody Drug Conjugates Market by Technology, 2018 - 2021, USD Million
TABLE 49 Rest of North America Antibody Drug Conjugates Market by Technology, 2022 - 2028, USD Million
TABLE 50 Key Information – Takeda Pharmaceutical Company Limited
TABLE 51 KEY INFORMATION – F. HOFFMANN-LA ROCHE LTD.
TABLE 52 KEY INFORMATION – ASTRAZENECA PLC
TABLE 53 Key Information – GlaxoSmithKline PLC
TABLE 54 Key Information – Pfizer, Inc.
TABLE 55 key information – Astellas Pharma, Inc.
TABLE 56 Key Information – Gilead Sciences, Inc.
TABLE 57 Key Information – Seagen Inc.
TABLE 58 Key Information – ADC Therapeutics SA
TABLE 59 Key Information – Daiichi Sankyo Company, Limited
List of Figures
FIG 1 Methodology for the research
FIG 2 KBV Cardinal Matrix
FIG 3 Key Leading Strategies: Percentage Distribution (2018-2022)
FIG 4 Key Strategic Move: (Partnerships, Collaborations & Agreements : 2018, May – 2022, Mar) Leading Players
FIG 5 Recent strategies and developments: Takeda Pharmaceutical Company Limited
FIG 6 Recent strategies and developments: Gilead Sciences, Inc.